The epidemiology and clinical features of 43 cases with novel coronavirus infection

doi:10.19871/j.cnki.xfcrbzz.2021.02.010

Abstract

Abstract: Objective To analyze the epidemiological and clinical characteristics of the second wave of patients with coronavirus disease 2019 (COVID-19) in Shenyang, and to provide guidance for the diagnosis and treatment of COVID-19. Methods The epidemiological and clinical characteristics of 43 patients with COVID-19 were collected and analyzed from December 23, 2020 to January 26, 2021 in the Sixth People's Hospital of Shenyang. Results Among the 43 patients, there were 14 males and 29 females, with an average age of （54.47±17.97） years old ranging from 16 to 95 years old; 51.2% patients had basic diseases; 86% patients had contact history with confirmed patients; the incubation period was 3 to 17 days; the main clinical manifestations of patients were fever and upper respiratory tract symptoms, and the main pulmonary CT manifestation was ground glass opacity. The laboratory examination of severe/critical patients showed that the number of leukocytes, C-reactive protein, D-dimer, interleukin-6 and procalcitonin were increased, and the number of lymphocytes was decreased. Conclusions The epidemic situation in Shenyang has the characteristics of older patients, more previous basic diseases, longer incubation period, higher proportion of severe/critical patients, and rapid disease progression. Compared with mild/common patients, severe/critical patients were more likely to suffer the infection and the damage in liver, kidney, coagulation, myocardium and cardiopulmonary function.

Key words: Coronavirus, Coranavirus disease 2019, Epidemiology, Clinical characteristics

Liu Xing, Liu Hongyan, Gu Ye, Wang Leishi, Tian Xia, Yu Hong, Hou Chunyang, Li Xinyue, Song Guannan, Wang Yan. The epidemiology and clinical features of 43 cases with novel coronavirus infection[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(2): 119-124.

References

[1] HU B, GUO H, ZHOU P, et al.Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021,19(3):141-154.
[2] ASSELAH T, DURANTEL D, PASMANT E,et al.COVID-19: Discovery, diagnostics and drug development[J]. J Hepatol, 2021, 74(1):168-184.
[3] 李倩,卢洪洲. 新型冠状病毒疫苗研究最新进展[J/CD]. 新发传染病电子杂志,2020,5(4):268-273.
[4] 丁金立,章礽荫. 新型冠状病毒肺炎放射检查方案与感染防控专家共识(试行第一版)[J/CD]. 新发传染病电子杂志,2020,5(2):65-73.
[5] 国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版)新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL][2021-01-07]. http://www.nhc.gov.cn/cms-search/downFiles/a449a3e2e2c94d9a856d5faea2ff0f94.pdf.
[6] BRANDON MH, MARIA HSDO, STEFANIE B, et al.Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis[J]. Clin Chem Lab Med, 2020, 58(7):1021-1028.
[7] HE ZP, ZHAO CH, DONG QM, et al.Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets[J]. Int J Infect Dis, 2005, 9(6):323-30.
[8] BRANDON MH.COVID-19, ECMO, and lymphopenia: a word of caution[J]. Lancet Respir Med, 2020,8(4):e24.
[9] HASAN KS, MANDEEP RM.COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal[J]. J Heart Lung Transplant, 2020, 39(5): 405-407.
[10] ZHANG W, ZHAO Y, ZHANG FC, et al.The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China[J]. Clin Immunol, 2020, 214: 108393.
[11] IAN H, RAYMOND P, MICHAEL AL, et al.C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis[J]. Ther Adv Respir Dis, 2020,14:1753466620937175.
[12] LIN L, LU LF, CAO W, et al.Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia[J]. Emerg Microbes Infect, 2020, 9(1):727-732.
[13] FATTORI E, CAPPELLETTI M, COSTA P, et al.Defective inflammatory response in interleukin 6-deficient mice[J]. J Exp Med, 1994, 180(4):1243-1250.
[14] HAN H, MA QF, LI C, et al.Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors[J]. Emerg Microbes Infect, 2020, 9(1):1123-1130.
[15] STUBER F, WRIGGE H, SCHROEDER S, et al.Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury[J]. Intensive Care Med, 2002, 28(7):834-841.
[16] POLLY EP, MARK DE, THOMPSONBT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury[J]. Crit Care Med, 2005, 33(1):1-6.
[17] LV YL, CHEN LK, LIANG XL, et al. Association between iron status and the risk of adverse outcomes in COVID-19[J]. Clin Nutr, 2020, S0261-5614(20):30654-3.
[18] TANG XP, FANG MQ, CHENG RM, et al.Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability[J]. Circ Res, 2020,127(5):651-663.
[19] HAL D, ANDREW MP.Hepcidin and the iron-infection axis[J]. Science, 2012, 338(6108): 768-772.
[20] INÊS S, TERESA P, SEBASTIAN M. IL-1 beta-mediated macrophagehepatocyte crosstalk upregulates hepcidin under physiological low oxygen levels[J]. Redox Biol, 2019,24:101209.
[21] XIONG SG, SHE HY, HEIGO T, et al.Signaling role of intracellular iron in NF-kappaB activation[J]. J Biol Chem, 2003,278(20):17646-54.
[22] JOHN BM, CARL HJ.Cytokine release syndrome in severe COVID-19[[J]. Science, 2020, 368(6490): 473-474.
[23] BEAT M, STEPHAN H, DAIANA S, et al.Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia[J]. BMC Infect Dis, 2007,7:10.
[24] JENNIE H, TIMOTHY G, CRAIG W.Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19[J]. Clin Med (Lond), 2020, 20(3):47.
[25] MÜLLER B, BECKER K, SCHÄCHINGER H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit[J]. Crit Care Med, 2000, 28:977-983.
[26] 宋玉燕,黄长先,周璐,等. 中西医结合疗法治疗31例重型新型冠状病毒肺炎临床疗效分析[J/CD]. 新发传染病电子杂志,2020,5(4):239-242.
[27] EVAN MB, SHMUEL S, ARTURO C, et al.Deployment of convalescent plasma for the prevention and treatment of COVID-19[J]. J Clin Invest, 2020, 30(6):2757-2765.
[28] KARTHICK R, NARAYANASAMY K, JAYANTHI R, et al.Convalescent plasma transfusion for the treatment of COVID-19: Systematic review[J]. J Med Virol. 2020,92(9):1475-1483.
[29] LIN HY.The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy[J]. Chin J Traumatol, 2020, 23(4):190-195.
[30] LUIGINA R, FRANCESCO B, CLAUDIA M, et al.Thymosina1: an endogenous regulator of inflammation, immunity, and tolerance[J]. Ann NY Acad Sci, 2017,1112:326-338.
[31] OHTAY, SUEKI K,YONEYAMA Y, et al.Immunomodulating activity of thymosin fraction 5 and thymosin Alpha 1 in immunosuppressed mice[J]. Cancer Immunol Immunother, 1983,15(2):108-13.
[32] MITCHELL H.Perspectives on the development of neutralizing antibodies against SARS-CoV-2[J]. Antib Ther, 2020, 3(2): 109-114.
[33] MUTHIAH V, ORLY V, THOMAS M, et al.Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19[J]. N Engl J Med, 382(17): 1653-1659.
[34] YAN RH, ZHANG YY, LI YN, et al.Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J]. Science, 367(6485): 1444-1448.
[35] YANG LF, LIU WH, YU X, et al.COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19[J]. Antib Ther, 2020,3(3): 205-212.